recombin
antibodi
highli
specif
detect
probe
research
diagnost
emerg
last
two
decad
fastest
grow
class
therapeut
protein
antibodi
gener
dramat
acceler
vitro
select
system
particularli
phage
display
increas
varieti
recombin
product
system
develop
rang
gramneg
posit
bacteria
yeast
filament
fungi
insect
cell
line
mammalian
cell
transgen
plant
anim
current
almost
therapeut
antibodi
still
produc
mammalian
cell
line
order
reduc
risk
immunogen
due
alter
nonhuman
glycosyl
pattern
howev
recent
develop
glycosylationengin
yeast
insect
cell
line
transgen
plant
promis
obtain
antibodi
humanlik
posttransl
modif
furthermor
smaller
antibodi
fragment
includ
bispecif
antibodi
without
glycosyl
success
produc
bacteria
advanc
clinic
test
first
therapeut
antibodi
product
nonmammalian
sourc
expect
come
next
year
review
focu
current
antibodi
product
system
includ
usabl
differ
applic
frenzel
et
al
recombin
antibodi
product
system
figur
recombin
antibodi
format
differ
applic
compar
igg
red
dark
red
variabl
region
blue
constant
region
green
artifici
peptid
linker
yellow
dhlx
repres
amphiphat
helic
use
dimer
scfv
fragment
today
antibodi
use
sever
applic
research
diagnost
therapi
use
mani
standard
assay
immunoblot
flow
cytometri
immunohistochemistri
addit
emerg
field
proteom
research
huge
need
binder
differ
protein
antigen
splice
variant
moreov
recombin
antibodi
use
diagnosi
differ
pathogen
toxin
past
decad
sever
antibodi
therapeut
applic
develop
primarili
target
inflammatori
tumor
diseas
sale
approv
therapeut
monoclon
antibodi
usa
eu
reach
billion
us
dollar
detect
differ
antigen
polyclon
antibodi
wide
use
research
diagnost
sera
contain
larg
divers
amount
differ
antibodi
unknown
specif
howev
polyclon
nonhuman
antibodi
may
exhibit
immun
respons
human
be
hamper
therapeut
use
exampl
snake
bite
therefor
product
monoclon
antibodi
mab
hybridoma
technolog
signific
mileston
gener
antibodi
therapeut
use
technolog
base
fusion
antibodi
produc
spleen
cell
immun
mice
rat
immort
myeloma
cell
line
main
obstacl
ineffici
immun
respons
highli
toxic
conserv
antigen
addit
nearli
antibodi
current
clinic
develop
humanorigin
least
human
aspect
prevent
immunogen
consequ
abbrevi
igg
immunoglobulin
g
mab
monoclon
antibodi
transgen
anim
especi
mice
develop
contain
human
immunoglobulin
gene
repertoir
solv
problem
immunogen
need
effici
immun
respons
immun
final
vitro
select
technolog
antibodi
phage
display
ribosom
display
provid
solut
gener
human
antibodi
new
antibodi
gener
technolog
increas
amount
antibodi
differ
applic
therefor
also
need
effici
product
system
immunoglobulin
g
igg
heterotetramer
molecul
consist
two
heavi
two
light
chain
respect
connect
via
disulfid
bond
heavi
light
chain
hc
lc
also
contain
intramolecular
disulfid
bond
stabil
structur
properti
requir
sophist
fold
apparatu
well
oxid
environ
gener
disulfid
bond
consequ
mani
tradit
express
host
provid
mechan
effici
product
igg
therefor
smaller
antibodi
fragment
develop
combin
easier
product
full
antigen
bind
capac
igg
figur
addit
develop
smaller
fragment
basi
vitro
antibodi
gener
system
antibodi
fragment
use
applic
epitop
bind
suffici
desir
effect
includ
therapeut
applic
viru
neutral
receptor
block
smallest
antigen
bind
fragment
immunoglobulin
maintain
complet
antigen
bind
site
fv
fragment
consist
variabl
v
region
solubl
flexibl
amino
acid
peptid
linker
use
connect
v
region
scfv
singl
chain
fragment
variabl
fragment
stabil
molecul
constant
c
domain
ad
v
region
obtain
fab
fragment
figur
today
scfv
fab
wide
use
antibodi
fragment
produc
prokaryot
antibodi
format
produc
prokaryot
eukaryot
cell
exampl
disulfidebond
stabil
scfv
dsscfv
singl
chain
fab
fragment
scfab
combin
scfv
fab
properti
well
diand
multimer
antibodi
format
like
dia
tria
tetrabodi
minibodi
miniab
compris
differ
format
consist
scfv
link
oligomer
domain
like
immunoglobulin
ch
domain
leucin
zipper
helix
turn
helix
motif
streptavidin
scfvscfv
tandem
bispecif
antibodi
format
combin
two
differ
antigen
bind
domain
one
molecul
smallest
antibodi
fragment
v
hh
cameloid
heavi
chain
antibodi
singl
domain
antibodi
dab
therapeut
applic
fc
moieti
immunoglobulin
essenti
method
action
mediat
effector
function
cellular
depend
cytotox
activ
complement
system
therefor
antibodi
fragment
fuse
fc
domain
regain
effector
function
avid
figur
depict
antibodi
format
develop
differ
applic
escherichia
coli
import
product
system
recombin
protein
reach
volumetr
yield
gram
per
liter
scale
extracellular
product
product
function
antibodi
fragment
key
success
secret
v
chain
periplasm
space
e
coli
oxid
environ
allow
correct
format
disulfid
bond
assembl
function
fv
fragment
strategi
also
allow
first
express
function
fab
fragment
e
coli
describ
product
recombin
antibodi
reduc
cytoplasm
compart
result
mostli
nonfunct
aggreg
recoveri
function
antibodi
fragment
cytoplasm
inclus
bodi
complet
denatur
refold
often
effici
stabl
cystein
free
mutant
scfv
success
produc
cytoplasm
e
coli
e
coli
strain
mutat
glutathion
thioredoxin
reductas
combin
coexpress
cytoplasm
chaperon
groel
trigger
factor
dnakj
well
signal
sequenceless
variant
periplasm
chaperon
dsbc
skp
increas
yield
function
fab
product
camelid
singl
domain
antibodi
vhh
coexpress
sulfhydryl
oxidas
increas
yield
cytoplasm
despit
effort
antibodi
fragment
produc
periplasm
e
coli
use
ntermin
leader
sequenc
target
periplasm
sec
pathway
exampl
signal
peptid
deriv
outer
membran
protein
ompa
alkalin
phosphatas
phoa
pectat
lyas
b
pelb
also
srp
pathway
use
antibodi
fragment
product
express
recombin
antibodi
usual
isol
periplasm
fraction
also
cultur
supernat
yield
function
scfv
fragment
improv
coor
overexpress
groesl
peptidyl
prolylci
transisomeras
fkpa
fold
helper
protein
function
express
also
increas
optim
cultiv
paramet
temperatur
media
addit
optim
paramet
depend
individu
antibodi
fragment
product
system
influenc
product
rate
high
yield
antibodi
fragment
produc
e
coli
mainli
provid
highcel
densiti
ferment
bioreactor
express
haptenspecif
scfv
produc
bioreactor
lead
yield
gl
compar
mgl
yield
antibodi
obtain
optim
shake
flask
product
mostli
address
higher
cell
densiti
bioreactor
recent
product
system
lex
bubbl
column
bioreactor
yield
lex
system
scfv
higher
yield
antilysozym
antibodi
higher
compar
shake
flask
incub
e
coli
strain
optim
eg
plasmid
stabil
addit
improv
product
yield
fab
format
requir
express
periplasm
transport
correct
fold
assembl
two
differ
polypeptid
chain
among
differ
vector
format
arrang
bicistron
vector
first
cistron
encod
light
chain
frontier
immunolog
b
cell
biolog
second
cistron
encod
fd
fragment
optim
even
aglycosyl
fullsiz
igg
success
produc
e
coli
view
raison
complet
igg
product
e
coli
doubt
cell
wallless
lform
gramneg
bacterium
proteu
mirabili
use
product
miniab
scfv
yield
total
scfv
function
scfv
differ
rang
mgl
total
scfv
mgl
function
scfv
howev
quit
recent
scfv
produc
success
pseudomona
putida
yield
mgl
interestingli
product
yield
decreas
use
scfv
gene
codon
optim
p
putida
gramposit
bacteria
directli
secret
protein
medium
due
lack
outer
membran
could
facilit
product
antibodi
fragment
gramposit
bacteria
bacillu
brevi
bacillu
subtili
bacillu
megaterium
alreadi
success
use
product
differ
antibodi
fragment
addit
b
megaterium
produc
alkalin
proteas
provid
high
stabil
plasmid
vector
growth
allow
stabl
transgen
express
long
term
cultiv
bioreactor
lactobacilli
also
test
antibodi
product
gener
regard
safe
gra
microorgan
date
two
lactobacillu
strain
use
product
scfv
lactobacillu
zeaecasei
lactobacillu
paracasei
gra
statu
lactobacilli
allow
direct
use
oral
applic
exampl
product
antistreptococcu
mutan
antibodi
fragment
prevent
tooth
decay
eukaryot
cell
develop
advanc
fold
posttransl
secret
apparatu
enhanc
secretori
product
antibodi
includ
full
immunoglobulin
compar
bacteria
yeast
combin
properti
eukaryot
cell
short
gener
time
eas
genet
manipul
robust
simpl
medium
requir
unicellular
microbi
host
moreov
yeast
use
ferment
food
product
sever
millennia
human
histori
produc
bacteri
endotoxin
gain
gra
statu
pave
way
toward
product
therapeut
protein
pichia
pastori
repres
major
yeast
strain
use
recombin
antibodi
product
yeast
like
saccharomyc
cerevisia
hansenula
polymorpha
schizosaccharomyc
pomb
schwanniomyc
occidentali
kluyveromyc
lacti
yarrowia
lipolytica
also
describ
protein
product
play
minor
role
p
pastori
show
overal
optim
capac
product
secret
heterolog
protein
cerevisia
secret
larg
amount
protein
simplifi
downstream
process
moreov
p
pastori
prefer
respiratori
growth
result
highcel
densiti
gl
dri
weight
probabl
promin
featur
p
pastori
metabol
methanol
sole
carbon
sourc
alcohol
oxidas
promot
strictli
control
methanol
commonli
use
recombin
protein
express
secretori
product
heterolog
protein
includ
antibodi
requir
aminotermin
signal
sequenc
target
yeast
secretori
pathway
cerevisia
mate
factor
alpha
alphafactor
prepro
peptid
commonli
use
secretori
signal
sequenc
follow
appropri
proteolyt
cleavag
site
sensit
golgi
resid
endoproteas
effici
releas
antibodi
secret
often
use
combin
exoproteas
site
express
scfv
antibodi
fragment
p
pastori
first
shown
ridder
et
al
yield
differ
scfv
rang
mgl
mgl
gl
function
scfv
obtain
optim
condit
bioreactor
coexpress
bip
llama
vhh
achiev
mgl
yield
cerevisia
even
shake
flask
cultiv
product
complex
yet
still
singlegeneencod
format
dimer
scfvfc
antibodi
p
pastori
achiev
product
level
mgl
antibodi
format
encod
two
gene
fab
igg
requir
fusion
two
differ
antibodi
chain
aminotermin
secretori
signal
sequenc
cotransform
yield
fab
produc
yeast
rang
mgl
shake
flask
cultiv
gl
bioreactor
limit
data
concern
fullsiz
igg
express
yeast
avail
earli
studi
mousehuman
chimer
antibodi
fab
fragment
produc
cerevisia
yield
igg
fab
respect
chimer
igg
mediat
tumor
specif
bind
adcc
antibodi
depend
cellular
cytotox
cdc
complement
depend
cytotox
use
p
pastori
gl
human
could
express
bioreactor
lower
transform
rate
compar
e
coli
must
consid
antibodi
librari
gener
rather
antibodi
product
moreov
frequenc
homolog
transform
yeast
higher
compar
higher
eukaryot
facilit
process
make
stabl
express
clone
specif
issu
heterolog
protein
express
yeast
circumv
optim
gene
sequenc
exampl
avoid
atrich
stretch
caus
prematur
transcript
termin
product
antibodi
fragment
yeast
increas
dna
shuffl
ineffici
secret
larger
heterolog
protein
kda
proteolysi
secret
protein
highcel
densiti
ferment
inappropri
glycosyl
human
glycoprotein
seriou
issu
requir
engin
yeast
strain
overexpress
chaperon
immunoglobulin
bind
protein
bip
protein
disulfid
isomeras
pdi
cerevisia
increas
scfv
secret
titer
twofold
eightfold
averag
yield
mgl
shake
flask
cultur
yeast
tend
hyperglycosyl
heterolog
protein
even
posit
glycosyl
nativ
mammalian
host
influenc
activ
antibodi
potenti
sourc
immunogen
advers
reaction
human
patient
p
pastori
exhibit
much
lower
hyperglycosyl
cerevisia
n
link
carbohydr
structur
alreadi
similar
mammalian
highmannos
core
unit
man
glcnac
moreov
genet
modifi
glycoengin
p
pastori
strain
gener
wwwfrontiersinorg
produc
human
glycosyl
pattern
therapeut
igg
antibodi
produc
glycoengin
yeast
achiev
result
compar
counterpart
trastuzumab
produc
mammalian
cell
unlik
igg
produc
wildtyp
yeast
produc
glycoengin
yeast
abl
mediat
antibodymedi
effector
function
product
process
employ
glycoengin
yeast
current
optim
commerci
antibodi
product
well
high
throughput
screen
filament
fungi
genera
trichoderma
aspergillu
capac
secret
larg
amount
protein
metabolit
medium
wide
use
food
biotechnolog
industri
exampl
niger
citric
acid
product
moreov
niger
subgenu
awamori
aspergillu
oryza
gain
obtain
gra
statu
two
promot
typic
use
express
antibodi
fungi
glucoamylas
promot
glaa
endoxylanas
promot
exla
antibodi
chain
usual
fuse
aminoterminu
glucoamylas
aspergillu
cellobiohydrolas
trichoderma
spec
respect
order
obtain
optim
secret
moreov
proteas
cleavag
site
like
kexb
introduc
releas
antibodi
glucoamylas
secret
yield
gl
igg
achiev
niger
antibodi
chain
fuse
glycoamylas
trichoderma
reesei
mgl
fab
fragment
obtain
chain
fuse
cellobiohydrolas
increas
yield
higher
natur
signal
peptid
awamori
use
product
sever
scfv
llama
vhh
antibodi
enzym
fusion
protein
yield
mgl
antiegfrvhh
achiev
oryza
use
takaamylas
signal
sequenc
amino
acid
aminotermin
region
rhizopu
oryza
lipas
fungal
proteas
result
protein
degrad
address
delet
mutant
chrysosporium
lucknowens
contain
tripl
proteas
delet
success
use
smallscal
product
screen
well
high
scale
bioreactor
product
recent
eukaryot
parasit
leishmania
tarentola
explor
express
system
differ
recombin
protein
one
major
advantag
express
system
mammalianlik
glycosyl
pattern
protozoa
abl
perform
oglycosyl
well
nglycosyl
highli
conserv
mammalian
consequ
l
tarentola
begun
use
product
recombin
antibodi
analysi
differ
signal
peptid
lead
protein
yield
mgl
purifi
scfv
insect
cell
repres
versatil
eukaryot
express
system
effici
transfect
insectspecif
virus
famili
baculovirida
particularli
autographa
californica
nuclear
polyhedrosi
viru
acnpv
baculovirus
highli
speciesspecif
consid
safe
human
mammalian
plant
infect
human
hepatocyt
mammalian
cell
line
includ
stabl
transduct
demonstr
cell
cultur
without
evid
viral
replic
gene
express
control
baculovir
promot
nonessenti
baculoviru
gene
involv
viral
life
cycl
like
polyhedrin
basic
replac
heterolog
gene
flexibl
viral
envelop
allow
packag
larg
heterolog
gene
sequenc
kb
heterolog
gene
control
strong
polyhedron
promot
express
level
rang
total
insect
cell
protein
baculovir
protein
express
normal
perform
insect
cell
line
like
spodoptera
frugiperda
cell
drosophila
melanogast
high
five
cell
trichopulsia
ni
high
five
cell
certain
advantag
cell
recombin
protein
express
secret
higher
protein
level
rapid
doubl
time
allow
quick
adapt
serumfre
medium
grow
suspens
cultur
contrast
cell
recommend
produc
hightit
viral
stock
due
higher
transfect
effici
recombin
protein
product
perform
smallscal
use
plate
shake
flask
well
larg
scale
use
spinner
flask
bioreactor
import
paramet
optim
baculovir
protein
product
multipl
infect
moi
product
length
usual
h
addit
proteas
inhibitor
due
releas
viral
proteas
temperatur
usual
media
ph
ph
secret
monomer
antiphox
scfv
obtain
level
mgl
bioreactor
cell
per
liter
h
moi
product
yield
mgl
achiev
variou
igg
immunoglobulin
produc
high
five
cell
show
mammalianlik
termin
galactosyl
residu
link
biantennari
glcnac
residu
contrast
absenc
sialyl
format
paucimannosid
structur
presenc
potenti
allergen
fucos
linkag
differ
mammalian
glycosyl
nevertheless
igg
produc
insect
cell
abl
mediat
effector
function
like
complement
bind
adcc
insect
cell
protein
express
improv
use
proteas
defici
baculoviru
strain
cell
line
addit
glycosyltransferas
gene
modif
obtain
glycosyl
pattern
compar
mammalian
cell
line
express
igg
insect
cell
control
strong
polyhedron
promot
result
extens
aggreg
probabl
caus
overload
cellular
fold
posttransl
process
apparatu
overexpress
er
resid
chaperon
bind
protein
bip
significantli
enhanc
level
solubl
secret
igg
ni
cell
enhanc
secret
igg
also
achiev
coexpress
protein
disulfid
isomeras
pdi
human
cytosol
chaperon
ni
cell
due
strong
usag
cellular
metabol
baculovir
protein
express
high
divers
posttransl
modif
observ
altern
baculovir
express
insect
cell
also
transfect
express
plasmid
transient
stabl
manner
usual
schneider
cell
melanogast
use
secretori
product
requir
signal
sequenc
like
honeybe
melittin
leader
stabl
transfect
frontier
immunolog
b
cell
biolog
drosophila
cell
line
monomer
dimer
antibodi
fragment
result
yield
immunoglobulin
g
product
use
baculoviru
express
system
demonstr
igg
effector
function
complement
bind
antirhesu
antibodi
produc
cell
mediat
lysi
rh
red
blood
cell
adcc
today
recombin
protein
pharmaceut
current
approv
therapeut
antibodi
still
produc
mammalian
cell
line
despit
rel
high
product
cost
difficult
handl
howev
advanc
mammalian
fold
secret
posttransl
apparatu
capabl
produc
antibodi
indistinguish
human
bodi
least
concern
immunogen
modif
moreov
also
highli
effici
secret
larg
complex
igg
combin
fold
posttransl
control
result
high
product
qualiti
reduc
effort
cost
subsequ
expens
downstream
process
step
risk
contamin
pathogen
bovin
spongiform
encephalopathi
tsebs
agent
elimin
welldocu
good
manufactur
practic
gmp
compliant
design
cell
substrat
chemic
defin
media
without
need
supplement
anim
serum
compon
mammalian
cell
cultur
technolog
reach
product
level
approxim
gl
igg
chines
hamster
ovari
cho
cell
today
industri
igg
product
level
often
exceed
gl
result
steadili
ongo
progress
mammalian
cell
cultur
technolog
mainli
due
improv
high
produc
cell
line
optim
product
media
prolong
product
process
highcel
densiti
highest
report
igg
product
titer
found
obtain
human
embryon
retin
cell
line
crucel
leiden
netherland
gl
gener
product
recombin
mammalian
cell
line
increas
initi
pg
antibodi
per
cell
per
day
pcd
pcd
today
antibodi
product
level
rare
exceed
pcd
higher
cellular
product
usual
correspond
lower
maximum
cell
densiti
product
process
produc
cell
line
also
genet
engin
regard
product
homogen
improv
metabol
reduc
apoptosi
induc
cell
cycl
arrest
allow
prolong
product
time
almost
week
highcel
viabil
cell
densiti
chines
hamster
ovari
cho
cell
common
cell
appli
commerci
product
biopharmaceut
cell
line
isol
gave
rise
rang
genet
differ
progeni
dukx
line
other
differ
protein
product
qualiti
achiev
yield
addit
cell
mous
myeloma
cell
babi
hamster
kidney
bhk
cell
human
embryon
kidney
cell
line
receiv
regulatori
approv
recombin
protein
product
although
glycosyl
pattern
mammalian
glycoprotein
similar
human
even
small
differ
influenc
pharmacokinet
effector
function
antibodi
altern
design
cell
line
improv
glycosyl
pattern
gener
exampl
human
neuron
precursor
cell
line
probiogen
berlin
germani
support
specif
complex
glycostructur
product
antibodi
requir
specif
posttransl
modif
suffer
instabl
suscept
proteolysi
cho
cell
variant
glycotop
also
produc
human
n
link
glycan
lack
fucos
improv
fcgammariii
bind
adcc
gener
stabl
master
cell
line
prerequisit
gmp
compliant
igg
product
therapeut
sector
order
guarante
long
term
product
stabil
antibodi
gene
express
cassett
stabli
integr
host
cell
genom
strong
promot
like
immedi
earli
cytomegaloviru
cmv
cellular
elong
factor
ef
promot
polyadenyl
site
simian
viru
sv
bovin
growth
hormon
bgh
improv
mrna
stabil
translat
effici
usual
implement
express
vector
furthermor
splice
mrna
known
promot
mrna
packag
transfer
cytosol
order
stabil
enhanc
gene
express
well
reduc
silenc
heterolog
transgen
igg
express
two
differ
gene
must
stabli
transfect
one
cell
clone
either
cotransfect
use
bicistron
express
vector
bicistron
vector
employ
intern
ribosom
entri
site
ire
allow
translat
two
cistron
transcript
encephalomyel
viru
ecmv
ire
shown
highest
effici
variou
mammalian
cell
line
mutat
ire
deriv
allow
control
translat
effici
relat
capdepend
cistron
ratio
light
heavi
chain
great
impact
secret
level
function
igg
long
term
stabil
ecmv
ire
contain
bicistron
construct
demonstr
even
absenc
select
pressur
month
differ
method
enhanc
antibodi
express
increas
number
antibodi
gene
copi
genom
gene
amplif
two
major
system
market
base
dihydrofol
reductas
dhfr
glutamyl
synthetas
gs
select
yield
function
produc
dhfr
cho
gsnso
equival
reach
gl
cell
howev
gene
amplif
also
caus
genet
instabl
remov
select
pressur
yield
antibodi
reduc
moreov
high
produc
cell
line
often
contain
copi
antibodi
gene
exampl
gl
final
antibodi
concentr
obtain
cell
contain
three
vector
copi
per
cell
factor
number
gene
copi
play
import
role
achiev
high
product
level
antibodi
therefor
industri
antibodi
express
platform
employ
effici
screen
system
order
isol
best
high
produc
howev
also
strategi
facilit
isol
high
produc
clone
overcom
neg
effect
integr
site
protect
cisregulatori
element
includ
insul
boundari
element
scaffoldmatrix
attach
region
smar
chromatin
open
element
wwwfrontiersinorg
antirepressor
element
introduc
vector
reduc
influenc
heterochromatin
stabil
transgen
express
silenc
block
inhibit
histon
deacetyl
use
butyr
could
enhanc
protein
express
level
cell
also
induc
apoptosi
recombin
enzym
like
bacteriophag
cre
recombinas
lambda
phage
integras
yeast
flp
recombinas
effici
catalyz
site
specif
integr
defin
chromosom
recombin
exchang
cassett
introduc
produc
cell
line
technolog
allow
express
igg
chain
singl
gene
due
posttransl
autocleavag
viral
proteas
encod
linker
subsequ
process
golgi
proteas
furin
gener
high
produc
cell
line
dramat
improv
acceler
howev
still
expens
timeconsum
labori
research
applic
larg
number
individu
antibodi
produc
transient
semist
mammalian
antibodi
express
much
suitabl
allow
fast
parallel
product
without
need
gener
produc
cell
line
moreov
transient
mammalian
antibodi
product
scale
employ
batch
fedbatch
bioreactor
process
l
product
volum
therefor
transient
antibodi
product
suitabl
smallscal
product
antibodi
screen
also
capabl
gener
gram
antibodi
human
embryon
kidney
hek
cell
line
wide
use
transient
protein
express
effici
transfect
plasmid
dna
deriv
transform
either
simian
viru
larg
antigen
term
epstein
barr
viru
ebv
nuclear
antigen
term
order
mediat
semist
episom
propag
vector
contain
origin
replic
ori
ebv
respect
transient
transfect
plasmid
dna
cell
also
perform
larg
scale
calcium
phosphat
transfect
cation
liposom
polym
like
polyethyleneimin
pei
recent
transient
product
igglik
scfvfc
antibodi
cell
line
genet
modifi
variant
truncat
version
grow
suspens
chemic
defin
serumfre
medium
achiev
volumetr
yield
gl
simpl
shake
flask
cultiv
improv
product
media
fedbatch
supplement
wellcontrol
bioreactor
process
allow
higher
cell
densiti
prolong
product
time
enhanc
yield
backliw
colleagu
combin
optim
peibas
transfect
highcel
densiti
coexpress
cell
cycl
regul
acid
fibroblast
growth
factor
valproic
acid
supplement
consequ
mainten
highcel
densiti
cellsmillilit
upscal
l
achiev
product
level
g
igg
within
week
transient
transfect
develop
transgen
plant
express
recombin
antibodi
becom
interest
especi
high
amount
requir
upscal
product
system
achiev
easili
compar
system
mammalian
cell
cultur
upscal
ferment
process
lead
increas
product
cost
theori
cost
iga
express
plant
compar
express
hybridoma
cell
gener
genet
modifi
dicotyledon
plant
mainli
done
transfer
express
cassett
transgen
help
agrobacterium
tumefacien
principl
gene
interest
clone
tdna
binari
plasmid
flank
two
bp
imperfect
repeat
case
express
transgen
control
one
two
copi
constitut
cauliflow
mosaic
viru
camv
addit
select
marker
locat
tdna
transfer
host
genom
effect
screen
success
transform
plant
integr
tdna
host
genom
nonhomolog
recombin
complet
plant
regener
transform
piec
plant
rb
procedur
requir
sever
month
transform
special
regener
protocol
transient
express
system
develop
allow
time
save
product
recombin
protein
mccormick
colleagu
design
tobacco
mosaic
viru
tmv
base
vector
secretori
express
differ
scfv
treatment
nonhodgkin
lymphoma
express
yield
nicotiana
benthamiana
crude
secretori
extract
techniqu
appli
express
idiotypescfv
person
vaccin
follicular
bcell
lymphoma
patient
phase
clinic
studi
studi
nearli
half
treat
patient
develop
antigen
specif
immun
respons
despit
differ
glycosyl
pattern
differ
glycosyl
pattern
mammalia
plant
one
main
obstacl
research
overcom
develop
therapeut
antibodi
express
plant
although
plant
abl
perform
complex
glycosyl
differ
glycosyl
pattern
particular
lead
immunogen
therapeut
protein
therefor
differ
strategi
develop
express
recombin
protein
mammalianlik
glycosyl
pattern
first
one
retent
protein
endoplasm
reticulum
er
erassoci
nglycosyl
lead
gener
oligomannosetyp
n
glycan
ident
plant
mammalian
one
side
effect
local
accumul
higher
level
er
second
approach
express
protein
mammalianlik
glycosyl
pattern
usag
glycoengin
plant
case
rna
interfer
rnai
use
downregul
endogen
lead
reduct
xylosyl
corefucosyl
n
glycan
second
type
glycoengin
plant
coexpress
gene
facilit
express
humanlik
n
glycan
even
frontier
immunolog
b
cell
biolog
planta
protein
sialyl
coexpress
six
mammalian
gene
increas
effort
put
adapt
nglycosyl
also
effort
engin
sialyl
mucintyp
oglycan
achiev
humanlik
glycosyl
pattern
altern
nonglycosyl
antibodi
mediat
protect
inhal
anthrax
spore
challeng
nonhuman
primat
show
improv
halflif
serum
rodriguez
colleagu
show
aglycosyl
form
nimotuzumab
current
phase
ii
clinic
studi
usa
canada
produc
tobacco
share
vitro
vivo
properti
well
antitumor
effect
nude
mice
glycosyl
form
transient
express
antibodi
plant
achiev
use
viral
vector
main
problem
approach
low
infect
vector
therefor
effici
transfer
tumefacien
combin
speed
high
express
rate
plant
rna
virus
system
use
express
monoclon
antibodi
nicotiana
benthamiana
yield
gkg
fresh
weight
principl
plantibodi
express
tobacco
n
tabacum
n
benthamiana
also
product
system
lemna
minor
duckwe
rice
cell
cultur
arabidopsi
thaliana
seed
medicago
sativa
alfalfa
lettuc
maiz
neutral
antibodi
express
endosperm
maiz
show
similar
even
better
neutral
properti
choderiv
counterpart
besid
transfect
transform
whole
plant
least
organ
monoclon
tobacco
cell
line
grow
suspens
develop
flow
cytometr
analysi
use
enrich
cell
express
fluoresc
marker
locat
tdna
antibodi
gene
use
method
enrich
high
express
cell
product
could
increas
shown
stabl
month
much
effort
set
establish
develop
plant
produc
antibodi
therapi
far
none
product
appear
market
despit
estim
dramat
reduct
product
cost
nevertheless
least
two
plant
deriv
antibodi
use
clinic
trial
carorx
develop
planet
biotechnolog
hayward
ca
usa
express
transgen
tobacco
antibodi
bind
streptococc
antigen
iii
mutan
major
caus
agent
bacteri
tooth
decay
prevent
attach
mutan
tooth
enamel
carorx
enter
clinic
phase
ii
second
plantmad
antiidiotyp
antibodi
nonhodgkinlymphoma
nhl
success
test
clinic
phase
studi
mention
recent
year
idea
express
human
antibodi
transgen
anim
increas
one
hand
human
antibodi
therapeut
deriv
hybridoma
technolog
still
labori
timeconsum
procedur
often
requir
gener
character
set
differ
human
version
antibodi
hand
mous
rat
deriv
antibodi
may
elicit
immun
respons
patient
one
method
gener
fulli
human
binder
antibodi
phage
display
technolog
besid
sever
research
develop
transgen
anim
product
express
human
monoclon
polyclon
antibodi
therefor
human
antibodi
mostli
express
milk
transgen
mice
goat
even
egg
transgen
chicken
first
step
toward
gener
human
antibodi
anim
immun
transfer
human
minilocu
contain
unrearrang
immunoglobulin
variabl
divers
join
element
link
human
mice
studi
approxim
extract
blymphocyt
express
human
antibodi
immun
larger
anim
contain
human
chromosom
immunoglobulin
loci
would
enabl
product
even
larger
amount
antibodi
therefor
transgen
cattl
develop
transfer
human
artifici
chromosom
vector
contain
entir
unrearrang
sequenc
human
immunoglobulin
heavi
lambda
light
chain
loci
improv
human
antibodi
proport
safeti
reason
regard
potenti
risk
bse
bovin
immunoglobulin
heavi
chain
locu
bovin
prion
protein
knock
final
transgen
cattl
carri
human
immunoglobulin
heavi
kappalight
chain
loci
use
immun
anthrax
protect
antigen
result
polyclon
antibodi
mixtur
consist
entir
human
chimer
immunoglobulin
show
high
activ
protect
vivo
mous
challeng
model
rabbit
cattl
use
express
bispecif
scfv
target
melanomaassoci
proteoglycan
human
molecul
cell
usag
differ
anim
sourc
gener
human
polyclon
sera
alreadi
initi
immunoglobulin
gene
loci
knock
livestock
pig
rabbit
review
approach
gener
transgen
anim
express
polyclon
human
antibodi
see
houdebin
much
energi
transgen
product
set
develop
human
mice
rat
well
establish
properti
gener
hybridoma
cell
speci
facilit
streamlin
approach
gener
cell
line
stabli
express
monoclon
antibodi
use
human
mice
antibodi
identifi
contrast
low
number
antigen
specif
hybridoma
occur
gener
clone
observ
therefor
usag
human
rat
suggest
circumv
problem
first
antibodi
develop
subnanomolar
affin
use
call
omnirat
today
mammalian
cell
line
repres
wide
use
express
system
product
recombin
antibodi
sever
host
develop
even
abl
produc
antibodi
humanlik
glycosyl
pattern
addit
sever
applic
glycosyl
wwwfrontiersinorg
pattern
play
critic
role
vitro
diagnost
research
therefor
bacteria
yeast
filament
fungi
insect
cell
employ
order
lower
product
cost
product
principl
transgen
plant
anim
highest
potenti
upscal
process
theoret
unlimit
product
amount
overview
recombin
antibodi
produc
differ
host
shown
tabl
howev
must
discrimin
yield
function
antibodi
purif
total
yield
antibodi
phage
display
widespread
method
develop
antibodi
fragment
scfv
fab
express
host
use
technolog
e
coli
known
best
genet
examin
organ
provid
larg
set
molecular
biolog
tool
genet
engin
consequ
antibodi
gener
product
perform
without
chang
product
system
use
highcel
densiti
ferment
yield
gl
depend
individu
antibodi
fragment
antibodi
fragment
express
e
coli
mainli
secret
periplasm
extract
gramposit
bacteria
lack
outer
membran
well
suit
biotechnolog
process
due
power
secret
apparatu
allow
easi
purif
directli
cultiv
supernat
howev
antibodi
product
system
employ
gramposit
bacteria
still
wwwfrontiersinorg
development
stage
howev
larger
antibodi
format
difficult
express
bacteria
express
furthermor
lack
glycosyl
apparatu
limit
use
effector
function
need
yeast
eukaryot
organ
capac
perform
posttransl
modif
addit
use
even
high
throughput
process
glycoengin
enabl
express
recombin
protein
humanlik
glycosyl
nevertheless
product
fullsiz
immunoglobulin
remain
challeng
compar
yeast
filament
fungi
difficult
gener
transform
clone
long
tradit
usag
biotechnolog
partial
use
express
igg
contrast
develop
protozoa
express
system
recombin
protein
antibodi
start
still
development
stage
howev
mammalianlik
glycosyl
pattern
present
promis
candid
exploit
insect
cell
contain
better
suit
protein
fold
secret
apparatu
prokaryot
high
robust
combin
less
sophist
requir
ferment
provid
advantag
compar
mammalian
cell
howev
develop
stabl
insect
cell
line
process
technolog
develop
far
consequ
mammalian
cell
line
wide
use
product
therapeut
antibodi
provid
sophist
fold
secret
apparatu
well
humanlik
glycosyl
product
high
level
recombin
antibodi
high
technic
effort
need
lead
rel
high
cost
maximum
report
yield
function
igg
gl
achiev
use
express
system
far
upscal
product
lead
high
reduct
product
cost
effici
reduct
product
cost
transgen
plant
use
repres
highli
scalabl
express
system
cultiv
easili
expand
without
gross
increas
cost
contrast
gener
transgen
plant
remain
complex
difficult
import
obstacl
transgen
plant
downstream
process
ton
plant
materi
may
process
howev
antibodi
product
milk
egg
anim
would
also
highli
scalabl
permit
easi
downstream
process
sever
livestock
anim
speci
develop
express
recombin
protein
gener
transgen
anim
also
labori
interest
approach
combin
human
transgen
anim
hybridoma
technolog
develop
human
antibodi
principl
univers
product
system
guarante
high
yield
recombin
antibodi
particularli
everi
antibodybas
molecul
caus
issu
term
express
